Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Jacobio Pharmaceuticals Group Co., Ltd. will showcase clinical data for their BET inhibitor, JAB-8263, at the upcoming 66th American Society of Hematology Annual Meeting in December 2024. The company, which is dedicated to creating innovative health solutions across six major signaling pathways, cautions there is no guarantee of JAB-8263’s successful development or marketability.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.
